Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Practical Nervous Diseases》 2017-17
Add to Favorite Get Latest Update

Effects of Jiangnian Kangshuan tablet combined with edaravone in the treatment of cerebral infarction patients

Yin Liujie;Li Yusheng;Xu Yuming;Zhengzhou Central Hospital Affiliated to Zhengzhou University;  
Objective To investigate the effects of Jiangnian Kangshuan tablet combined with edaravone on the treatment of cerebral infarction and on hemorheology and superoxide dismutase(SOD)activity,and to explore the mechanism of antiplatelet aggregation.Methods 72 patients with cerebral infarction in Zhengzhou Central Hospital Affiliated to Zhengzhou University from February 2013 to September 2016 were randomly divided into observation group(n=36)and control group(n=36).Both groups were given edaravone treatment,and the observation group additionally received Jiangnian Kangshuan tablet treatment.The total effective rate of the two groups was compared after two weeks,and the hemorheological indexes including erythrocyte sedimentation rate(ESR),packed-cell volume(PCV),whole blood reduced viscosity(RV),platelet adhesion rate(PADT),SOD,plasma TXB_2 and 6-keto-PCF1αwere measured.Results(1)Curative effect:The total effective rate was 91.67%in the observation group and 69.44%in the control group,and the difference was statistically significant(χ~2=5.675,P0.05);(2)Hemorheological indexes:Compared with the control group,the PCV,RX and PADT in the observation group were significantly lower than those in the control group at 2 weeks after treatment(P0.05);(3)SOD activity:Two weeks After treatment,the SOD level of the two groups was higher than that before treatment,and the observation group showed higher SOD level than the control group(P0.05);(4)Anti-platelet aggregation mechanism:TXB_2 level was decreased and 6-keto-PCF1αlevel was increased in both two groups after treatment,and compared with control group,the observation group showed lower TXB_2 level and higher 6-keto-PCF1αlevel(all P0.05).Conclusion The treatment of Jiangnian Kangshuan tablet combined with edaravone can improve the hemorheology and the activity of superoxide dismutase with beneficial clinical efficacy.
【CateGory Index】: R743.33
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved